Business
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
CHICAGO, July 09, 2025--MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/f4f67ced389930577737762f35ee478a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oOeWOwm0AbCQX6CzSmnbgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f4f67ced389930577737762f35ee478a","width":960,"height":365},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7ascv3P7jZ2UtnkWkGcYiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f4f67ced389930577737762f35ee478a","width":1000,"height":380}},"lazy":false},{"type":"text","content":"CHICAGO, July 09, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial’s entry into another continent marks a key milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine (THIO). Screening for the trial is ongoing in Europe and Asia.","length":561,"tagName":"p"},{"type":"text","content":"Trial Design: The expansion study evaluates ateganosine in heavily pre-treated patients in third-line (3L) NSCLC who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy. Two treatment arms are being studied: ateganosine sequenced with cemiplimab (Libtayo®) and ateganosine monotherapy. Regeneron is supplying Libtayo for the combination cohort.","length":376,"tagName":"p"},{"type":"text","content":"Strategic Opportunity: NSCLC represents one of the largest global oncology indications. The market was valued at $34.1B in 2024, and is projected to reach $68.8B by 2033 with a projected CAGR of 8.1%.1","length":201,"tagName":"p"},{"type":"text","content":"Current Data: As of May 15, 2025, the median overall survival (OS) for the 22 patients in the third-line treatment was 17.8 months, with a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated in the trial’s heavily pre-treated p...